In­te­gral Mol­e­c­u­lar's off-tar­get pro­tein bind­ing ar­ray nabs first spot in FDA pi­lot to speed new drug de­vel­op­ment tools

The FDA on Wednes­day of­fi­cial­ly kicked off a pi­lot pro­gram de­signed to ex­pand its qual­i­fi­ca­tion of out-of-scope drug de­vel­op­ment tools (DDTs) by se­lect­ing In­te­gral Mol­e­c­u­lar’s Mem­brane Pro­teome Ar­ray as the first par­tic­i­pant.

The cell-based ar­ray from In­te­gral Mol­e­c­u­lar seeks to eval­u­ate off-tar­get pro­tein bind­ing and to de­ter­mine the speci­fici­ty and pre­clin­i­cal safe­ty of an­ti­bod­ies, CAR-T cell ther­a­pies, and oth­er bio­ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER